ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025)
ENDRA Life Sciences (NDRA) posted quarterly Current Deferred Revenue of $328610.0 for Q2 2025, down 15.9% quarter-over-quarter from $390722.0 in Q1 2025.
ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Current Deferred Revenue for 2 consecutive years, with $328610.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Current Deferred Revenue changed N/A year-over-year to $328610.0; the TTM figure through Jun 2025 stood at $328610.0 (changed N/A YoY), while the FY2024 annual figure was $799284.0, changed N/A from the prior year.
- Current Deferred Revenue fell to $328610.0 in Q2 2025 per NDRA's latest filing, from $390722.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $910556.0 in Q3 2024 and bottomed at $328610.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn |
| 10 | ENDRA Life Sciences | 5.44 Mn | 5.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 328,610.00 |
| Mar 31, 2025 | 390,722.00 |
| Dec 31, 2024 | 799,284.00 |
| Sep 30, 2024 | 910,556.00 |